Dr Michael Schuliga is a University of Newcastle scientist researcher with extensive experience investigating lung cell biology and the effects of therapeutics in lung injury and disease.

Based at the Hunter Medical Research Institute, Dr Schuliga is currently advancing idiopathic pulmonary fibrosis (IPF) research in pre-clinical studies designed for definitive translational outcomes. His main research objective is to better understand the role of ageing mechanisms such as senescence and mitochondrial dysfunction in the pathology of IPF.

He has been involved in and led NHMRC Project Grants and is currently principal investigator for a research program sponsored by Boehringer Ingelheim examining alveolar epithelial cell injury in IPF.

Dr Schuliga’s increasing research profile is highlighted by numerous first- or senior-author publications in premier specialist respiratory, clinical, biogerontology or pharmacology journals.